Li Ting, Lin Guang-Yao, Zhong Li, Zhou Yan, Wang Jia, Zhu Yue, Feng Yang, Cai Xiao-Qing, Liu Qing, Nosjean Olivier, Boutin Jean A, Renard Pierre, Yang De-Hua, Wang Ming-Wei
The National Center for Drug Screening and the CAS Key Laboratory of Receptor Research, Shanghai Institute of Materia Medica, Chinese Academy of Sciences, Shanghai 201203, China.
University of Chinese Academy of Sciences, Beijing 100049, China.
Acta Pharmacol Sin. 2017 Jul;38(7):1024-1037. doi: 10.1038/aps.2017.15. Epub 2017 May 15.
Recent evidence shows that high glucose levels recruit carbohydrate response element-binding protein, which binds the promoter of thioredoxin-interacting protein (txnip), thereby regulating its expression in β-cells. Overexpression of txnip not only induces β-cell apoptosis but also reduces insulin production. Thus, the discovery of compounds that either inhibit TXNIP activity or suppress its expression was the focus of the present study. INS-1E cells stably transfected with either a txnip proximal glucose response element connected to a luciferase reporter plasmid (BG73) or full-length txnip promoter connected to a luciferase reporter plasmid (CL108) were used in primary and secondary high-throughput screening campaigns, respectively. From 256 000 synthetic compounds, a small molecule compound, W2476 [9-((1-(4-acetyl-phenyloxy)-ethyl)-2-)adenine], was identified as a modulator of the TXNIP-regulated signaling pathway following the screening and characterized using a battery of bioassays. The preventive and therapeutic properties of W2476 were further examined in streptozotocin-induced diabetic and diet-induced obese mice. Treatment with W2476 (1, 5, and 15 μmol/L) dose-dependently inhibited high glucose-induced TXNIP expression at the mRNA and protein levels in INS-1E cells and rat pancreatic islets. Furthermore, W2476 treatment prevented INS-1E cells from apoptosis induced by chronic exposure of high glucose and enhanced insulin production in vitro. Oral administration of W2476 (200 mg·kg·d) rescued streptozotocin-induced diabetic mice by promoting β-cell survival and enhancing insulin secretion. This therapeutic property of W2476 was further demonstrated by its ability to improve glucose homeostasis and insulin sensitivity in diet-induced obese mice. Thus, chemical intervention of the TXNIP-regulated signaling pathway might present a viable approach to manage diabetes.
近期证据表明,高血糖水平会募集碳水化合物反应元件结合蛋白,该蛋白与硫氧还蛋白相互作用蛋白(TXNIP)的启动子结合,从而调节其在β细胞中的表达。TXNIP的过表达不仅会诱导β细胞凋亡,还会降低胰岛素的产生。因此,发现能够抑制TXNIP活性或抑制其表达的化合物是本研究的重点。分别用连接有荧光素酶报告质粒的TXNIP近端葡萄糖反应元件(BG73)或连接有荧光素酶报告质粒的全长TXNIP启动子稳定转染的INS-1E细胞,用于初次和二次高通量筛选实验。从256000种合成化合物中,一种小分子化合物W2476 [9 - ((1 - (4 - 乙酰苯氧基) - 乙基) - 2 - )腺嘌呤]在筛选后被鉴定为TXNIP调节信号通路的调节剂,并通过一系列生物测定进行了表征。在链脲佐菌素诱导的糖尿病小鼠和饮食诱导的肥胖小鼠中进一步研究了W2476的预防和治疗特性。用W2476(1、5和15 μmol/L)处理可剂量依赖性地抑制INS-1E细胞和大鼠胰岛中高糖诱导的TXNIP在mRNA和蛋白质水平的表达。此外,W2476处理可防止INS-1E细胞因长期暴露于高糖而诱导的凋亡,并在体外增强胰岛素的产生。口服W2476(200 mg·kg·d)可通过促进β细胞存活和增强胰岛素分泌来挽救链脲佐菌素诱导的糖尿病小鼠。W2476改善饮食诱导的肥胖小鼠的葡萄糖稳态和胰岛素敏感性的能力进一步证明了其这种治疗特性。因此,对TXNIP调节信号通路的化学干预可能是治疗糖尿病的一种可行方法。